Akeso, Inc. ( (HK:9926) ) has provided an update.
Akeso, Inc. announced a significant decrease in its financial performance for the year ended December 31, 2024, with revenue dropping by 53.08% compared to the previous year. Despite an increase in commercial sales, the company’s gross profit also fell by 58.23%, leading to a net loss of RMB501.1 million, primarily due to the absence of a substantial upfront payment received in 2023 from a collaboration with SUMMIT.
More about Akeso, Inc.
Akeso, Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on developing and commercializing innovative therapies, with a market focus on collaboration and licensing agreements.
YTD Price Performance: 22.90%
Average Trading Volume: 8,983,256
Technical Sentiment Signal: Sell
Current Market Cap: HK$66.96B
For detailed information about 9926 stock, go to TipRanks’ Stock Analysis page.